相关实验视频

Updated: Jul 19, 2025

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

乙柏林抑制了Helicobacter pylori,并通过降低尿酶表达的调节来减少宿主亡和炎症损伤

Huimin Wu¹, Xinrui Xie², Qin Tang³

¹Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China; Chongqing Haiwang Biological Engineering Co., Chongqing, 409900, China.

Journal of ethnopharmacology

|August 16, 2023

概括

乙柏林 (EPI) 通过抑制尿素酶活性和减少胃炎症,有效地对抗抗生素耐药的Helicobacter pylori (H. pylori). 这种传统中医药化合物为H. pylori感染提供了一个有希望的替代方案.

科学领域:

药理学药理学是指药理学的学科.
微生物学微生物学
胃肠病学胃肠病学

背景情况:

Helicobacter pylori (H. pylori) 抗生素耐药性的增加需要新的治疗策略.
中国传统医药中的Rhizoma Coptidis表现出强大的抗H. pylori作用.
作为一个关键的化物,Epiberberine (EPI) 显示出潜力,但它的H. pylori清除和尿酶抑制机制需要阐明.

研究的目的:

为了评估Epiberberine (EPI) 对H.pylori的抑制作用.
探索EPI对Helicobacter pylori尿酶 (HPU) 的多方面的作用.

主要方法:

在体外和体内测试 (MIC,MBC,生长动力学,TEM,动物模型) 评估了EPI的抗H. pylori疗效和耐药性发展.
生物化学和分子对接研究研究了EPI与HPU的相互作用.
转录组分析和RT-PCR检查了ureB基因表达.
通过MTT测定,霍希斯特染色,JC-1,西斑和格里斯测定,评估了EPI对胃上皮细胞的影响.

主要成果:

EPI在体外表现出显著的抗H. pylori活性,诱导细菌碎片化和无抵抗的亡.
在体内研究证实了EPI的H. pylori清除和减少H. pylori诱导的胃炎症.
EPI表现出三重机制:抑制ureB表达,直接结合并抑制HPU活性,并减轻HPU诱导的亡和炎症.

结论:

乙柏林 (EPI) 是一种对抗H. pylori的有效药物,可以作为抗生素的替代品.
EPI通过向尿酶活性和降低 ureB 表达的调节来减少宿主胃亡和炎症.

关键词:

埃皮贝贝林 (Epiberberine) 是一种蛋白质.在H. Pylori的研究中,带复合性疾病的根茎.文字转录学 (Transcriptomics) 是一个学科.在UreB中,UreB是UreB.在Urease中使用.

更多相关视频

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Expression, Purification, and Antimicrobial Activity of S100A12

Expression, Purification, and Antimicrobial Activity of S100A12

Published on: May 13, 2017

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...